Home Newsfeeds Keybanc Maintains Overweight on WESCO International, Lowers Price Target to $150

Keybanc Maintains Overweight on WESCO International, Lowers Price Target to $150

Keybanc analyst Todd Thomas maintains WESCO International (NYSE:WCC) with a Overweight and lowers the price target from $165 to $150.

byBenzinga Newsdesk

July 12, 2022

1 minute read

Keybanc analyst Todd Thomas maintains WESCO International (NYSE:WCC) with a Overweight and lowers the price target from $165 to $150.

Alibaba Partners With Saudi Arabia And UAE Firms As China Gets Closer To Gulf

By Benzinga Neuro

February 14, 6:12 AM

This development comes at a time when the Gulf nations are strengthening their ties with China, seeking investments to diversify their economies beyond oil.

BABA

This Analyst With 84% Accuracy Rate Sees Over 19% Upside In Dell Technologies – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

By Lisa Levin

December 4, 8:19 AM

U.S. stocks closed higher on Friday, with the S&P 500 index jumping to a new closing high for 2023.

ATI

Did Black Adam Save DC Comics? How The Rock Could Revive Warner Brothers Stock

By Chris Katje

October 24, 12:08 PM

Best known as the home of Batman and Superman, DC Comics has a library of hundreds of comic book characters. Parent company Warner Bros Discovery (NASDAQ: WBD) now appears to have a new hit superhero movie from the DC Comics universe.

DIS

HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $4

By Benzinga Newsdesk

August 16, 6:27 AM

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Medicenna Therapeutics (NASDAQ:MDNA) with a Buy and lowers the price target from $5 to $4.

MDNA

Keybanc Maintains Overweight on WESCO International, Lowers Price Target to $150

Related Posts

Alibaba Partners With Saudi Arabia And UAE Firms As China Gets Closer To Gulf

This Analyst With 84% Accuracy Rate Sees Over 19% Upside In Dell Technologies – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

Did Black Adam Save DC Comics? How The Rock Could Revive Warner Brothers Stock

HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $4